ストックスクリーナーアプリを入手
4.605
3.20%
-0.235
Coya Therapeutics Inc (COYA) 最新ニュース
(COYA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Coya Therapeutics (COYA): Analyst Maintains 'Buy' Rating with St - GuruFocus
D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Coya Therapeutics advances ALS and FTD clinical trials in 2026 By Investing.com - Investing.com India
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders - PharmiWeb.com
Coya Therapeutics Reports Strong Cash Position and Runway - TipRanks
Coya Therapeutics advances ALS and FTD clinical trials in 2026 - Investing.com
Will Coya Therapeutics Inc outperform its industry peers2025 Winners & Losers & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Momentum Shift: Is PHAT currently under institutional pressureQuarterly Portfolio Review & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
COYA-302: De-Risked Treg Platform With Compelling FTD Data and ALS Phase 2 Catalyst Supporting Buy Rating - TipRanks
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Can Candel Therapeutics Inc. stock attract ESG capital inflows2025 Momentum Check & Consistent Return Strategy Ideas - ulpravda.ru
Is Coya Therapeutics Inc. stock a safe buy before earnings2025 AllTime Highs & Verified High Yield Trade Plans - Улправда
Is Coya Therapeutics Inc. stock a bargain at current levels2025 Year in Review & High Accuracy Swing Entry Alerts - Улправда
Is Coya Therapeutics Inc. stock a buy in volatile marketsJuly 2025 Trade Ideas & High Accuracy Investment Entry Signals - Улправда
Is Coya Therapeutics Inc. stock cheap compared to fundamentals2025 Key Lessons & Technical Pattern Based Buy Signals - Улправда
Support Test: How CERo Therapeutics Holdings Inc. stock benefits from global expansionTrade Analysis Report & Weekly Stock Performance Updates - ulpravda.ru
Chardan Capital Reiterates "Buy" Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Aug Intraday: How Coya Therapeutics Inc. stock reacts to job market dataJuly 2025 Price Swings & Comprehensive Market Scan Reports - Улправда
Coya Therapeutics: Early COYA 302 Validation, Regulatory De-Risking, and Upcoming Catalysts Support Buy Rating - TipRanks
Coya Therapeutics, Inc. Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients - marketscreener.com
How Coya Therapeutics Inc. stock reacts to job market data2025 Price Momentum & Entry and Exit Point Strategies - ulpravda.ru
COYA: Analyst Maintains Buy Rating and $15 Target Price | COYA S - GuruFocus
Coya Therapeutics Reports Positive Frontotemporal Dementia Study Data - TipRanks
Coya Therapeutics Announces Positive Study Results for FTD Treatment - TradingView — Track All Markets
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients - Business Wire
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Panic Selling: How Coya Therapeutics Inc stock reacts to job market dataMarket Volume Report & Technical Pattern Recognition Alerts - moha.gov.vn
Coya Therapeutics, Inc.Common Stock (NQ: COYA - FinancialContent
Coya Therapeutics: Clinical Momentum, Extended Cash Runway, and DCF-Derived Upside Support Reiterated Buy and $18 Target - TipRanks
Coya Therapeutics (NASDAQ:COYA) Given Buy Rating at D. Boral Capital - Defense World
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for CO - PharmiWeb.com
Coya Therapeutics announces FDA acceptance of COYA 302 IND application - TipRanks
US COYA 302 trial in ALS expands to Canada after regulatory nod - ALS News Today
H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock at $18 - Investing.com Canada
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD) - BioSpace
COYA Stock Receives Consistent "Buy" Rating from D. Boral Capita - GuruFocus
Coya Therapeutics advances COYA 303 for inflammatory diseases - MSN
D. Boral Capital Reiterates "Buy" Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
(COYA) Risk Channels and Responsive Allocation - Stock Traders Daily
Coya announces Health Canada acceptance of COYA 302 clinical trial application - MSN
S P Trends: Will Coya Therapeutics Inc stock pay special dividendsJuly 2025 Price Swings & Long-Term Safe Return Strategies - Bộ Nội Vụ
Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Is Coya Therapeutics Stock Built to Withstand More Downside? - Trefis
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - BioSpace
Trading the Move, Not the Narrative: (COYA) Edition - Stock Traders Daily
D. Boral Capital Maintains Coya Therapeutics (COYA) Buy Recommendation - Nasdaq
D. Boral Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Coya Therapeutics receives clinical trial application acceptance from Health Canada - marketscreener.com
Coya Therapeutics, Inc. Receives Clinical Trial Application Acceptance from Health Canada to Proceed with the COYA302 Alstars Trial for the Treatment of Amyotrophic Lateral Sclerosis - marketscreener.com
PRN_FinancialWrapper - FinancialContent
Coya Therapeutics receives $4.2M milestone payment - MSN
Moving Averages: Why retail investors pile into Coya Therapeutics Inc. stockEarnings Recap Report & Reliable Entry Point Alerts - Улправда
Why retail investors pile into Coya Therapeutics Inc. stock2025 Trading Volume Trends & Low Volatility Stock Recommendations - Улправда
Analyst Upgrade: Is Coya Therapeutics Inc. stock a bargain at current levels2025 Volatility Report & Capital Protection Trading Alerts - DonanımHaber
Can Coya Therapeutics Inc. stock maintain operating marginsJuly 2025 Big Picture & Safe Capital Investment Plans - Улправда
Coya Therapeutics Receives $4.2M Milestone Payment - TipRanks
Coya Therapeutics Receives Milestone Payment for ALS Trial - TradingView — Track All Markets
Coya Therapeutics (NASDAQ: COYA) reports $4.2 million ALS trial payment - Stock Titan
1.25%
3.00%
大文字化:
|
ボリューム (24 時間):